Healthcare

Popular Topics in Healthcare

Subscribe to Updates in Healthcare

By RSS

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

GLG News by Acular/Acular LS (Ketorolac Tromethamine) Prescribers: Ophthalmologists (US)

Articles with lock require a subscription to GLG News |

Request a free trial

May 7, 2008

LASIK IS AN EXCELLENT PROCEDURE FOR THE APPROPRIATE CANDIDATES
Analysis of: LASIK Worries? Some May See Better with Alternatives | www.washingtonpost.com
Author: GLG Expert Contributor

The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years: Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone. About 1 out of 4 patients that consider lasik are actually good candidates...

April 7, 2008

The Next Big Thing in Cataract and Lens Based Surgery: The Light Adjustable Lens (LAL)
Analysis of: Pilot trial for toric correction with light-adjustable lens yields promising early results | ophthalmologytimes.modernmedicine.com
Author: GLG Expert Contributor

The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery. The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...

January 29, 2008
Bausch makes foray into presbyopic arena
Analysis of: Bausch & Lomb announces acquisition of eyeonics | www.osnsupersite.com
Author: Barry Schechter, Director of Corneal and External Diseases, Florida Eye Microsurgical Institute, Inc.

With the recent trends of presbyopic correction , Bausch and Lomb has now entered the arena.

November 8, 2007

U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo
Analysis of: Allergan, Inc. Receives FDA Approval For COMBIGAN™ (Brimonidine Tartrate/timolol Maleate Ophthalmic Solution) 0.2%/0.5% | www.medicalnewstoday.com
Author: GLG Expert Contributor

The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...

October 31, 2007

GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATION
Analysis of: Genentech revisits plan for Avastin | www.sfgate.com
Author: GLG Expert Contributor

In the two weeks since Genetech made its announcement that it would limit the availability of Avastin to ophthalmologists for use in treating wet macular degeneration the outcry from patients, ophthalmologists, politicians, and the American Academy of OPhthalmology has been so great that Genetech is...

October 29, 2007

American Academy of Ophthalmology Issues Press Statement Criticizing Genentech's Decision to Limit Avastin Availability for the Treatment of Wet Macular Degeneration
Analysis of: Ophthalmologists Concerned About AMD Patients’ Access To Avastin | aao.org
Author: GLG Expert Contributor

The American Academy of Ophthalmology said the recent decision by Genentech to limit availability of Avastin (bevacizumab) to compounding pharmacies could have a significant negative impact on the care of patients with age-related macular degeneration [AMD]. Dr. Charles Wilkinson, president of the AAO,...

October 22, 2007

BREAKING NEWS: GENETECH TO RESTRICT THE AVAILABILITY OF AVASTIN IN ORDER TO LIMIT ITS USE OVER ITS MORE EXPENSIVE FDA APPROVED MEDICINE (LUCENTIS) FOR WET MACULAR DEGENERATION
Analysis of: Genentech to cease supplying bevacizumab to compounding pharmacies | www.osnsupersite.com
Author: GLG Expert Contributor

Genentech, Inc. is suspending sales of Avastin (bevacizumab) to compounding pharmacies in the United STates, in an effort to curb its non approved use for wet macular degenration. Recently, ophthalmologists have begun using the antiangiogenic cancer drug off-label to treat retinal neovascularization...

October 16, 2007

Interesting Approach to the Lucrative Dry Eye Market
Analysis of: Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501 | www.pipelinereview.com
Author: GLG Expert Contributor

Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens. Although the small...

October 15, 2007

Restriction on Avastin distribution will add to Genenetech's bottom line.
Analysis of: Maker Seeks to Restrict Cancer Drug Used on Eye | www.nytimes.com
Author: GLG Expert Contributor

Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label. Although this amount of sales places Lucentis well within the blockbuster...

September 24, 2007

OMEGA 3 FATTY ACIDS CAN HOLD PROMISE IN TREAMENT OF MANY EYE DISEASES
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth | www.pnas.org
Author: GLG Expert Contributor

Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...

Page : 1 2 3 4 5 6 Next1 to 10 of 56

More GLG News in
Healthcare

GLG News: What Experts Think Is Important

Generated at 2008-09-07T01:45:17.680

GLG News by Acular/Acular LS (Ketorolac Tromethamine) Prescribers: Ophthalmologists (US)

More GLG News inHealthcare

GLG News: What Experts Think Is Important

More GLG News in
Healthcare